Latest California Healthline Stories
Seeking Refills: Aging Pharmacists Leave Drugstores Vacant in Rural America
Independent pharmacists who want to retire often have trouble attracting new pharmacists to take over their practices, particularly in rural areas. That can cause smaller towns to lose their pharmacies. With many pharmacists near retirement, the problem may only get worse.
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
With Overdose Deaths Surging, Advocates on the Ground Push for Over-the-Counter Naloxone
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
Con más muertes por sobredosis, defensores claman por una naloxona de venta libre
La administración Biden ha destinado $30 millones a programas de reducción de daños por adicciones. Pero defensores dicen que la principal barrera es que la naloxona sigue siendo de venta bajo receta.
Texas Toughens Ban on Medication-by-Mail Abortions With Jail Time and Hefty Fine
Last week, on the same day the Supreme Court heard a case that could overturn Roe v. Wade, the landmark ruling on abortion rights, Texas enacted a law that creates criminal penalties for anyone who prescribes medication abortions via telehealth or mail.
Journalists Explore Health Care Disparities and Policy Pitfalls
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Success of Covid Antiviral Pills Hinges on Access to Speedy and Accurate Tests
The promising antiviral drugs to treat covid can halt hospitalizations and deaths, but only if they’re given to patients within three to five days of their first symptoms, a narrow window many people won’t meet. Here’s why.
KHN’s ‘What the Health?’: Boosting Confusion
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits
The number of pharmacies dispensing 340B discounted drugs soared to more than 31,000 this year. Drugmakers struck back by halting some discounts. Hospitals say they are losing millions of dollars — and cutting back services to patients — as a result.